Agendia

Oct 21, 2020

MammaPrint® Approved for Reimbursement in Germany

Oct 01, 2020

Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation

Sep 17, 2020

Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress

Aug 25, 2020

MINDACT Study Shows MammaPrint® Provides Widespread Health System Cost Savings

Jul 29, 2020

Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer

Jul 27, 2020

Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology

May 29, 2020

Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)

May 29, 2020

Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

May 07, 2020

Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences

Apr 16, 2020

Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients